SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY)
INCY 93.48+1.0%Oct 31 9:30 AM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (3138)6/8/2017 5:22:36 PM
From: tuck   of 3202
 
Navoximod, OTOH, appears to be a direct inhibitor of IDO. Here's the underlying patent app:

Imidazole Derivatives as IDO Inhibitors

Interestingly, in light of Indoximod's MOA, Indoximod and Navoximod were shown to be synergistic at 2013 AACR:

NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy

See the upper right of the poster. Would NLNK try this combo now that they own both?

I understand that losing validation from Genentech is a serious blow, but are these assets as worthless as AF suggests (he wondered why NLNK trades above cash)?

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News